Founded in 2022, we are a spin-out from Singapore-MIT Alliance for Research and Technology (SMART) and NTU Lee Kong Chian School of Medicine with proprietary platform technologies centered around selective bacterial targeting. The vast majority of current antibacterial ingredients in the market do not respect our native microbiome and eliminate all microorganisms indiscriminately including the good bacteria. This leads to 1. Adverse side effects such as skin irritations and infections due to microbiome imbalance2. Antibiotic Resistance, which is rising to dangerously high levels around the worldArrowBiome's platform technologies address this issue by engineering antibacterial proteins to target specific bacterial strains for indications such as acne and body odour.
Social Link - Linkedin: http://www.linkedin.com/company/arrowbiome
Employee Count: 3
Keywords: biotechnology research